EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

High prevalence but no current clinical relevance of methyldibromo glutaronitrile since its ban in Turkey in 2015

Esen Özkaya iD, Ömer Mangır

Contact Dermatitis · 2024

DOI: 10.1111/cod.14642 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contact Dermatitis, 2024. Verfasst von Esen Özkaya und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, İstanbul Faculty of Medicine, İstanbul University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Dermatitis, Allergic Contact, Nitriles, Cosmetics, Patch Tests. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Regulatory actions significantly reduced methyldibromo glutaronitrile (MDBGN)‐induced allergic contact dermatitis (ACD) from cosmetics in Europe. Turkey banned MDBGN in 2015.

Objectives

To assess sensitization and ACD rates to MDBGN before and after its ban in Turkey.

Methods

Data from 2653 consecutively patch tested patients between 1996 and 2023 with MDBGN 0.1% pet. ( n = 573) or 0.2%–0.3% pet. ( n = 1310) or 0.5% pet. ( n = 770) were analysed. MDBGN was tested as MDBGN/phenoxyethanol (PE) in 1434 patients.

Results

The sensitization prevalence was 1.7% (45/2653), peaking at 5.3% in 2018 and 2023 with MDBGN 0.3% pet. There was a two‐fold male predominance, with patients exclusively ≥20 years old. None of the patients reacted to PE. ACD occurred in 0.7% (19/2653), mainly affecting hands and linked to non‐occupational exposure (78.9%), particularly from rinse‐off/leave‐on cosmetics. The pattern of ‘middle‐aged men with hand eczema and fragrance allergy' was particularly notable. Occupational ACD was rare (21.1%), occurring mainly in hairdressers from hair gel. Positive reactions with current clinical relevance dropped from 48.3% (1996–2014) to zero after 2015 ( p < 0.001).

Conclusions

The ban effectively reduced MDBGN‐induced ACD in Turkey, yet the prevalence of positive patch test reactions remains high, likely due to past exposures or other undisclosed sources. We suggest continued testing of MDBGN in the EBS in Turkey.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, Allergic ContactNitrilesCosmeticsPatch TestsHumansTurkeyMaleFemaleAdultPrevalenceMiddle AgedYoung AdultAdolescentHand DermatosesPreservatives, PharmaceuticalClinical Relevance

Stichwörter der Autor:innen

Euxyl K400allergic contact dermatitiscosmeticsdibromodicyanobutaneepidemiologymethyldibromo glutaronitrilenon‐occupationaloccupationalpatch testphenoxyethanol

Substanzen

1,2-dibromo-2,4-dicyanobutaneNitrilesCosmeticsPreservatives, Pharmaceutical

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, İstanbul Faculty of Medicine, İstanbul University, Istanbul, Turkey.

ORCID-Profile: Esen Özkaya

Zitieren

APA

Özkaya, E., & Mangır, Ö. (2024). High prevalence but no current clinical relevance of methyldibromo glutaronitrile since its ban in Turkey in 2015. Contact Dermatitis. https://doi.org/10.1111/cod.14642

Vancouver

Özkaya E, Mangır Ö. High prevalence but no current clinical relevance of methyldibromo glutaronitrile since its ban in Turkey in 2015. Contact Dermatitis. 2024. doi:10.1111/cod.14642

BibTeX
@article{zkaya2024,
  author = {Özkaya, Esen and Mangır, Ömer},
  title = {High prevalence but no current clinical relevance of methyldibromo glutaronitrile since its ban in Turkey in 2015},
  journal = {Contact Dermatitis},
  year = {2024},
  doi = {10.1111/cod.14642}
}
Kostenlos starten →